Approximately one in every ten cancers is driven by an inherited genetic mutation — a pathogenic variant present at birth in every cell of the body. These are not the sporadic mutations that accumulate over a lifetime from environmental exposures and replication errors; they are hardwired into the genome, passed from parent to child, conferring dramatically elevated cancer risk across generations. Genetic testing for hereditary cancer syndromes has become one of the most clinically actionable applications of genomic medicine.
Hereditary vs Sporadic Cancer: The 10% Rule
The vast majority of cancers — approximately 90% — are sporadic, arising from acquired mutations that accumulate over a lifetime. These somatic mutations are present only in tumor cells and are not inherited. The remaining 10% are hereditary, caused by germline mutations present in every cell. People with hereditary cancer syndromes are born with one defective copy of a tumor suppressor gene; if the second copy is lost in a single cell through environmental damage or chance, that cell loses growth control and cancer can develop.
The distinction matters enormously for clinical management. A BRCA1 mutation carrier faces a 55–72% lifetime risk of breast cancer and a 39–44% risk of ovarian cancer, compared to population-average risks of approximately 13% and 1.3% respectively, as documented in a 2017 JAMA meta-analysis of over 30,000 mutation carriers. Someone with Lynch syndrome — caused by mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM) — faces a 52–82% lifetime risk of colorectal cancer, plus elevated risks of endometrial, ovarian, gastric, and urinary tract cancers. Knowledge of a hereditary cancer syndrome triggers a fundamentally different screening and prevention strategy.
The Key Genes: Beyond BRCA1/2
While BRCA1 and BRCA2 are the most widely recognized hereditary cancer genes — with a prevalence of approximately 1 in 400 people in the general population and 1 in 40 among Ashkenazi Jewish individuals — the landscape extends far beyond BRCA.
- Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM): The most common hereditary colorectal cancer syndrome, also elevating risk of endometrial, ovarian, gastric, and urinary tract cancers. Lynch syndrome affects an estimated 1 in 279 people.
- TP53 (Li-Fraumeni syndrome): Mutations in this critical tumor suppressor gene confer near-certain cancer risk over a lifetime, including sarcomas, breast cancer, brain tumors, and adrenocortical carcinoma, often in childhood or early adulthood. Lifetime cancer risk approaches 100% for women and 73% for men.
- PTEN (Cowden syndrome): Elevated risks of breast, thyroid, endometrial, and renal cancers, with lifetime breast cancer risk exceeding 85%.
- APC (Familial Adenomatous Polyposis): Causes hundreds to thousands of colon polyps beginning in adolescence, with colorectal cancer nearly inevitable by age 40–50 without prophylactic colectomy.
- ATM, CHEK2, PALB2: Moderate-penetrance breast cancer genes elevating risk to 20–40% lifetime, increasingly included in multi-gene panels.
Single-Gene vs Multi-Gene Panel Testing
When Angelina Jolie wrote about her BRCA1 test in 2013, single-gene testing was the standard. Today, multi-gene panel testing — analyzing 30 to 80+ cancer-associated genes simultaneously — is recommended by the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology. A patient who meets BRCA testing criteria may also carry a pathogenic variant in a different gene with different cancer risks and management recommendations.
A 2019 study in JAMA Oncology found that among women meeting BRCA1/2 testing criteria, multi-gene panels identified pathogenic variants in non-BRCA genes at a rate of 5–7% — findings missed entirely by single-gene testing. However, multi-gene panels produce more Variants of Uncertain Significance (VUS) because more genes are tested and many have less established clinical data. Genetic counseling before and after testing is essential to decide on appropriate panel size.
| Testing Approach | Genes Analyzed | Best For | VUS Rate |
|---|---|---|---|
| Single-gene BRCA | BRCA1, BRCA2 | Known family mutation | ~2–3% |
| Syndrome-specific panel | 5–15 genes | Clear syndrome suspicion | ~5–8% |
| Comprehensive panel | 30–80+ genes | Broad family history | ~20–35% |
| Whole genome | All known genes | Comprehensive lifetime | ~30–40% |
What Results Mean: Positive, Negative, and VUS
A positive result means a pathogenic or likely pathogenic variant was identified in a gene with established cancer risk. This does not mean cancer is inevitable — it means risk is substantially elevated, and enhanced screening or preventive measures should be discussed with a genetic counselor and relevant specialists. A negative result is more nuanced: it rules out the genes tested, but does not rule out hereditary cancer risk from genes not on the panel, or from variants not detectable by current technology. A negative BRCA test does not mean no hereditary cancer risk exists — it only means no pathogenic variant was found in BRCA1 or BRCA2.
A Variant of Uncertain Significance (VUS) is particularly challenging — the genetic change exists, but there is insufficient evidence to classify it as disease-causing or benign. A VUS should not be used for clinical decision-making. Over time, as databases grow, many VUS are reclassified: a 2022 study in Genetics in Medicine found that approximately 9% of VUS were reclassified within 5 years, with the majority downgraded to benign. Patients with VUS results should inquire about periodic reanalysis programs.
Risk-Reducing Options After a Positive Result
A positive result initiates a personalized risk management plan. Enhanced screening options include annual breast MRI alternating with mammography starting at age 25–30, and transvaginal ultrasound plus CA-125 blood tests for ovarian cancer surveillance. Risk-reducing surgery provides the greatest protection: prophylactic bilateral mastectomy reduces breast cancer risk by 90–95%, while prophylactic salpingo-oophorectomy (ovary and fallopian tube removal) reduces ovarian cancer risk by 80–96% and breast cancer risk by 50% when performed before menopause.
For Lynch syndrome, annual colonoscopy starting at age 20–25 reduces colorectal cancer mortality by an estimated 65%, and prophylactic hysterectomy with bilateral salpingo-oophorectomy should be discussed after childbearing is complete. Chemoprevention — tamoxifen or raloxifene for breast cancer, aspirin for Lynch syndrome colorectal cancer — offers additional risk reduction. Cascade testing of at-risk family members is critical: siblings and children each have a 50% chance of carrying the same pathogenic variant.
Insurance Coverage and GINA Protections
Most commercial insurers cover genetic testing when NCCN criteria are met. Under the Affordable Care Act, BRCA testing is covered without cost-sharing as a preventive service for women at elevated risk. The Genetic Information Nondiscrimination Act (GINA) of 2008 prohibits health insurers and employers from using genetic information for coverage or employment decisions, though GINA does not apply to life insurance, disability insurance, or long-term care insurance — a gap that some states have addressed with additional legislation. Many testing laboratories offer patient-pay options of $250–$350 for individuals who do not meet insurance criteria or prefer not to use insurance.